ArticleMagnetic resonance in medicine2025
Multi-site feasibility and reproducibility study on UTE 3D phosphorous MRSI using novel rosette trajectory (PETALUTE).
Article in Magnetic resonance in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Feasibility of ConcurrentNMR in biomedicine · 2026Article
- Advanced methods in deuterium metabolic imaging.Magma (New York, N.Y.) · 2026Review
- Neuroimaging evidence of mitochondrial dysfunction and inflammation in psychiatric disorders: a review.Psychoradiology · 2026Review
- Multi-site feasibility and reproducibility study on UTE 3D phosphorous MRSI using novel rosette trajectory (PETALUTE).Magnetic resonance in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aims (1) to implement a robust acquisition, fully automated reconstruction, and processing pipeline using a novel rosette k-space pattern for UTE
methodsA multi-center feasibility/reproducibility study was conducted for the novel UTE
resultsThis novel acquisition and advanced processing techniques yielded high-quality spectra and enabled the detection of the critical brain metabolites at three different sites with different hardware specifications. In vivo, feasibility with an acceleration factor of 4 in 6.75 min resulted in a mean Cramér-Rao lower bounds below 20% for phosphocreatine (PCr), adenosine triphosphate (ATP), phosphomonoesters (PME), and a mean coefficient of variation for ATP/PCr below 20%.
conclusionWe demonstrated that UTE
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.